Pancreatic Cancer Research

ResearcherCancer Prevention Institute of CaliforniaActive in the last 2 years

Núria Malats

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2538-3784; OpenAlex author ID A5037804113, A5038459530. Sources: OpenAlex.

Their work

Papers
76 (first author 2, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
208
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 6 papers · 2016: 1 paper · 2017: 4 papers · 2018: 3 papers · 2019: 4 papers · 2020: 12 papers · 2021: 13 papers · 2022: 3 papers · 2023: 3 papers · 2024: 5 papers · 2025: 9 papers · 2026: 7 papers

Papers 50 of 76

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  3. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  4. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  5. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  6. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  7. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  8. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Last author DOI 10.1002/ijc.35397↗
  9. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  10. End-to-end prognostication in pancreatic cancer by multimodal deep learning: a retrospective, multicenter study. Co-author DOI 10.1007/s00330-025-11694-y↗
  11. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  12. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  13. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  14. A Common CTRB misfolding variant associated with pancreatic cancer risk causes ER stress and inflammation in mice. Co-author DOI 10.1136/gutjnl-2024-333406↗
  15. A fusion-based deep-learning algorithm predicts PDAC metastasis based on primary tumour CT images: a multinational study. Last author DOI 10.1136/gutjnl-2024-334237↗
  16. Development of a consensus molecular classifier for pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13073-025-01568-9↗
  17. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.neo.2024.100975↗
  18. The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival. Co-author DOI 10.1016/j.pan.2024.08.014↗
  19. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery. Co-author DOI 10.1016/j.xcrm.2024.101557↗
  20. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  21. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-330480↗
  22. Artificial Intelligence in Pancreatic Ductal Adenocarcinoma Imaging: A Commentary on Potential Future Applications. Co-author DOI 10.1053/j.gastro.2023.04.003↗
  23. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  24. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  25. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  26. Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study. Co-author DOI 10.1053/j.gastro.2022.03.054↗
  27. A faecal microbiota signature with high specificity for pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-324755↗
  28. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33464↗
  29. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. Co-author DOI 10.1002/ueg2.12123↗
  30. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  31. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  32. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  33. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Last author DOI 10.1097/cej.0000000000000588↗
  34. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Last author DOI 10.1136/gutjnl-2019-319990↗
  35. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  36. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Last author DOI 10.1186/s13073-020-00816-4↗
  37. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  38. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features. Co-author DOI 10.3389/fimmu.2021.730746↗
  39. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer O… Co-author DOI 10.3390/cancers13071612↗
  40. Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS N… Co-author DOI 10.3390/cancers13153687↗
  41. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. Co-author DOI 10.1016/j.ebiom.2020.102675↗
  42. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  43. Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1097/cej.0000000000000572↗
  44. Bratislava Statement: consensus recommendations for improving pancreatic cancer care. Co-author DOI 10.1136/esmoopen-2020-001051↗
  45. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  46. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Last author DOI 10.1158/1055-9965.epi-19-1027↗
  47. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0091↗
  48. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  49. DNA Methylation-Derived Immune Cell Profiles, CpG Markers of Inflammation, and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0378↗
  50. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗

Closest collaborators

The 25 strongest of 208 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Francisco X. Real · 25 shared papers, 2011–2026 · strength 2.41
  2. Alfredo Carrato · 21 shared papers, 2011–2025 · strength 1.79
  3. William Greenhalf · 13 shared papers, 2015–2025 · strength 1.08
  4. Casper W.F. van Eijck · 5 shared papers, 2024–2025 · strength 1.08
  5. Esther Molina‐Montes · 12 shared papers, 2017–2022 · strength 1.06
  6. Matthias J. Löhr · 11 shared papers, 2017–2025 · strength 1.06
  7. Casper H.J. van Eijck · 5 shared papers, 2024 · strength 0.99
  8. Thomas Mathias Gress · 10 shared papers, 2017–2025 · strength 0.97
  9. Eithne Costello · 12 shared papers, 2015–2024 · strength 0.90
  10. Tatjana Crnogorac‐Jurcevic · 11 shared papers, 2015–2025 · strength 0.89
  11. Rita Teresa Lawlor · 8 shared papers, 2017–2025 · strength 0.83
  12. Aldo Scarpa · 9 shared papers, 2017–2025 · strength 0.79
  13. Christoph W. Michalski · 8 shared papers, 2017–2026 · strength 0.77
  14. Luis Muñoz‐Bellvís · 9 shared papers, 2017–2025 · strength 0.76
  15. J. Enrique Domínguez‐Muñoz · 9 shared papers, 2017–2025 · strength 0.76
  16. Jorg H. Kleeff · 9 shared papers, 2017–2025 · strength 0.76
  17. Evangelina López de Maturana · 4 shared papers, 2021–2025 · strength 0.75
  18. Dana A. M. Mustafa · 3 shared papers, 2024 · strength 0.67
  19. John J. Hermans · 3 shared papers, 2023–2025 · strength 0.64
  20. Megan Schuurmans · 3 shared papers, 2023–2025 · strength 0.64
  21. Paulina Gómez-Rubio · 9 shared papers, 2017–2022 · strength 0.63
  22. Bas Groot Koerkamp · 3 shared papers, 2024 · strength 0.63
  23. Julie Earl · 6 shared papers, 2015–2025 · strength 0.61
  24. Linda Sharp · 8 shared papers, 2017–2024 · strength 0.58
  25. Bo Kong · 8 shared papers, 2017–2024 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.